TY - JOUR
T1 - IgM myeloma
T2 - A multicenter retrospective study of 134 patients
AU - Castillo, Jorge J.
AU - Jurczyszyn, Artur
AU - Brozova, Lucie
AU - Crusoe, Edvan
AU - Czepiel, Jacek
AU - Davila, Julio
AU - Dispenzieri, Angela
AU - Eveillard, Marion
AU - Fiala, Mark A.
AU - Ghobrial, Irene M.
AU - Gozzetti, Alessandro
AU - Gustine, Joshua N.
AU - Hajek, Roman
AU - Hungria, Vania
AU - Jarkovsky, Jiri
AU - Jayabalan, David
AU - Laubach, Jacob P.
AU - Lewicka, Barbara
AU - Maisnar, Vladimir
AU - Manasanch, Elisabet E.
AU - Moreau, Philippe
AU - Morgan, Elizabeth A.
AU - Nahi, Hareth
AU - Niesvizky, Ruben
AU - Paba-Prada, Claudia
AU - Pika, Tomas
AU - Pour, Ludek
AU - Reagan, John L.
AU - Richardson, Paul G.
AU - Shah, Jatin
AU - Spicka, Ivan
AU - Vij, Ravi
AU - Waszczuk-Gajda, Anna
AU - Gertz, Morie A.
N1 - Publisher Copyright:
© 2017 Wiley Periodicals, Inc.
PY - 2017/8
Y1 - 2017/8
N2 - IgM myeloma is a rare hematologic malignancy for which the clinicopathological features and patient outcomes have not been extensively studied. We carried out a multicenter retrospective study in patients with diagnosis of IgM myeloma defined by >10% marrow involvement by monoclonal plasma cells, presence of an IgM monoclonal paraproteinemia of any size, and anemia, renal dysfunction, hypercalcemia, lytic lesions and/or t(11;14) identified by FISH. A total of 134 patients from 20 centers were included in this analysis. The median age at diagnosis was 65.5 years with a male predominance (68%). Anemia, renal dysfunction, elevated calcium and skeletal lytic lesions were found in 37, 43, 19, and 70%, respectively. The median serum IgM level was 2,895 mg dL−1 with 19% of patients presenting with levels >6,000 mg dL−1. International Staging System (ISS) stages 1, 2, and 3 were seen in 40 (33%), 54 (44%), and 29 (24%) of patients, respectively. The malignant cells expressed CD20 (58%) and cyclin D1 (67%), and t(11;14) was the most common cytogenetic finding (39%). The median overall survival (OS) was 61 months. Higher ISS score was associated with worse survival (P = 0.02). Patients with IgM myeloma present with similar characteristics and outcomes as patients with more common myeloma subtypes.
AB - IgM myeloma is a rare hematologic malignancy for which the clinicopathological features and patient outcomes have not been extensively studied. We carried out a multicenter retrospective study in patients with diagnosis of IgM myeloma defined by >10% marrow involvement by monoclonal plasma cells, presence of an IgM monoclonal paraproteinemia of any size, and anemia, renal dysfunction, hypercalcemia, lytic lesions and/or t(11;14) identified by FISH. A total of 134 patients from 20 centers were included in this analysis. The median age at diagnosis was 65.5 years with a male predominance (68%). Anemia, renal dysfunction, elevated calcium and skeletal lytic lesions were found in 37, 43, 19, and 70%, respectively. The median serum IgM level was 2,895 mg dL−1 with 19% of patients presenting with levels >6,000 mg dL−1. International Staging System (ISS) stages 1, 2, and 3 were seen in 40 (33%), 54 (44%), and 29 (24%) of patients, respectively. The malignant cells expressed CD20 (58%) and cyclin D1 (67%), and t(11;14) was the most common cytogenetic finding (39%). The median overall survival (OS) was 61 months. Higher ISS score was associated with worse survival (P = 0.02). Patients with IgM myeloma present with similar characteristics and outcomes as patients with more common myeloma subtypes.
UR - https://www.scopus.com/pages/publications/85019759763
U2 - 10.1002/ajh.24753
DO - 10.1002/ajh.24753
M3 - Article
C2 - 28383205
AN - SCOPUS:85019759763
SN - 0361-8609
VL - 92
SP - 746
EP - 751
JO - American journal of hematology
JF - American journal of hematology
IS - 8
ER -